Sort   by:  
 Page size 
UnknownHedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.
Not available
S-EPMC8361230 | biostudies-literature
GenomicsHomologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harboring evidence of defective homologous recombination (HR) DNA repair. Within a phase 2 window clinical trial, RIO trial (EudraCT 2014-003319-12), we investigate the activity of PARP inhibitors in 43...
EGAS00001004405 | EGA
TranscriptomicsMutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
Homologous recombination (HR) and nucleotide excision repair (NER) are the two most frequently disabled DNA repair pathways in cancer. HR-deficient breast, ovarian, pancreatic and prostate cancers respond well to platinum chemotherapy and PARP inhibitors. However, the frequency of HR deficiency in g...
ORGANISM(S): Homo sapiens 
2024-02-23 | GSE256301 | GEO
ProteomicsNeonGreen-POLQ knock-in in Human embryonic kidney 293 cells VS Human embryonic kidney 293 cells
Replication stress (RS) can lead to the formation of DNA double strand breaks (DSBs) and threatens genomic stability. Homologous recombination (HR) pathway is essential to prevent RS and repairs associated DSBs. Upon excessive RS or HR deficiency, DSBs can persist in mitosis, wherein DNA damage resp...
ORGANISM(S): Homo sapiens (Human) 
2023-09-18 | PXD029585 | Pride
Polθ binding partners in human cells 
ProteomicsαKG-mediated carnitine synthesis promotes homologous recombination via histone acetylation
Homologous recombination (HR) deficiency enhances sensitivity to DNA damaging agents commonly used to treat cancer. In HR-proficient cancers, metabolic mechanisms driving response or resistance to DNA damaging agents remain unclear. We identified that depletion of KG sensitizes HR-proficient cells t...
ORGANISM(S): Homo sapiens (Human) 
2026-03-30 | PXD060690 | Pride
Ovarian cancer Epigenetics Dna damaging agents Isocitrate dehydrogenase Glutamine Acetylcarnitine Tmlhe Cyclin e 
ProteomicsThe molecular landscape of homologous recombination deficient, end-stage, high grade serous ovarian cancer
High grade serous cancer (HGSC) is frequently characterizsed by homologous recombination (HR) DNA repair deficiency, and while most such tumours are sensitive to initial treatment, acquired resistance is common. We undertook a multi-omics approach to interrogating mechanisms of resistance, using mul...
ORGANISM(S): Homo sapiens (Human) 
2023-02-27 | PXD030034 | Pride
Ovarian cancer  high grade serous cancer  multi-omics  acquired resistance 
TranscriptomicsAlpha-ketoglutarate -mediated carnitine synthesis promotes homologous recombination via histone acetylation
Homologous recombination (HR) deficiency enhances sensitivity to DNA damaging agents commonly used to treat cancer. In HR-proficient cancers, metabolic mechanisms driving response or resistance to DNA damaging agents remain unclear. Here we identified that depletion of alpha-ketoglutarate (αKG) sens...
ORGANISM(S): Homo sapiens 
2025-02-26 | GSE289735 | GEO
TranscriptomicsTargeting DKC1-mediated pseudouridylation combined with PARPi induces synthetic lethality in homologous recombination-proficient tumors [RNA-Seq]
Poly(ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment landscape of BRCA-mutant tumors by exploiting synthetic lethality arising from homologous recombination (HR) deficiency. Yet, a substantial proportion of solid tumors remain HR-proficient and thus less responsive to PAR...
ORGANISM(S): Homo sapiens 
2026-08-14 | GSE313124 | GEO
GenomicsTargeting DKC1-mediated pseudouridylation combined with PARPi induces synthetic lethality in homologous recombination-proficient tumors [ATAC-seq]
Poly(ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment landscape of BRCA-mutant tumors by exploiting synthetic lethality arising from homologous recombination (HR) deficiency. Yet, a substantial proportion of solid tumors remain HR-proficient and thus less responsive to PAR...
ORGANISM(S): Homo sapiens 
2026-08-14 | GSE312874 | GEO
OtherTargeting DKC1-mediated pseudouridylation combined with PARPi induces synthetic lethality in homologous recombination-proficient tumors
Poly(ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment landscape of BRCA-mutant tumors by exploiting synthetic lethality arising from homologous recombination (HR) deficiency. Yet, a substantial proportion of solid tumors remain HR-proficient and thus less responsive to PAR...
ORGANISM(S): Homo sapiens 
2026-08-14 | GSE312872 | GEO
Sort   by:  
 Page size